145 related articles for article (PubMed ID: 37899949)
1. Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions.
Hoeh B; Garcia CC; Banek S; Klümper N; Cox A; Ellinger J; Schmucker P; Hahn O; Mattigk A; Zengerling F; Becker P; Erdmann K; Buerk BT; Flegar L; Huber J; Kalogirou C; Zeuschner P
Clin Transl Immunology; 2023; 12(10):e1471. PubMed ID: 37899949
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma.
Klümper N; Schmucker P; Hahn O; Höh B; Mattigk A; Banek S; Ellinger J; Heinzelbecker J; Sikic D; Eckstein M; Strauß A; Zengerling F; Hölzel M; Zeuschner P; Kalogirou C
Clin Transl Immunology; 2021; 10(12):e1358. PubMed ID: 34925829
[TBL] [Abstract][Full Text] [Related]
3. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N; Sikic D; Saal J; Büttner T; Goldschmidt F; Jarczyk J; Becker P; Zeuschner P; Weinke M; Kalogirou C; Breyer J; Burger M; Nuhn P; Tully K; Roghmann F; Bolenz C; Zengerling F; Wirtz RM; Muders M; Kristiansen G; Bald T; Ellinger J; Wullich B; Hölzel M; Hartmann A; Erben P; Ritter M; Eckstein M
Eur J Cancer; 2022 May; 167():13-22. PubMed ID: 35366569
[TBL] [Abstract][Full Text] [Related]
5. Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors.
Schüttke V; Kusiek C; Fuessel S; Thomas C; Buerk BT; Erdmann K
Clin Transl Oncol; 2024 May; 26(5):1117-1128. PubMed ID: 37695463
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients.
Kankkunen E; Penttilä P; Peltola K; Bono P
Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053
[TBL] [Abstract][Full Text] [Related]
7. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA; Moik F; Steinlechner S; Posch F; Mayer MC; Sandner AM; Berton F; Schlintl V; Koch L; John N; Wurm R; Pichler M; Bauernhofer T; Reimann P; Wohlkönig C; Richtig E; Winder T; Preusser M; Jost PJ; Ay C; Gerger A; Terbuch A; Riedl JM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097343
[TBL] [Abstract][Full Text] [Related]
8. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Klümper N; Saal J; Berner F; Lichtensteiger C; Wyss N; Heine A; Bauernfeind FG; Ellinger J; Brossart P; Diem S; Schmid S; Joerger M; Frueh M; Ritter M; Hölzel M; Flatz L; Bald T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292517
[TBL] [Abstract][Full Text] [Related]
9. Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma.
Tachibana H; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Kondo T; Tanabe K; Takagi T
Clin Genitourin Cancer; 2022 Feb; 20(1):e81-e88. PubMed ID: 34772629
[TBL] [Abstract][Full Text] [Related]
10. Early C-reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma.
Qin Q; Kou X; Zheng Y; Zhou F; Zhang X; Liu H
J Hepatocell Carcinoma; 2023; 10():2009-2019. PubMed ID: 37954495
[TBL] [Abstract][Full Text] [Related]
11. Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab.
Haas M; Lein A; Fuereder T; Schnoell J; Brkic FF; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Oct; 41(5):727-736. PubMed ID: 37603206
[TBL] [Abstract][Full Text] [Related]
12. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
[TBL] [Abstract][Full Text] [Related]
14. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C
Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357
[TBL] [Abstract][Full Text] [Related]
15. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
17. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Teishima J; Kobatake K; Shinmei S; Inoue S; Hayashi T; Ohara S; Mita K; Hasegawa Y; Maruyama S; Kajiwara M; Shigeta M; Mochizuki H; Moriyama H; Fujiwara S; Matsubara A
Urol Oncol; 2017 Nov; 35(11):662.e1-662.e7. PubMed ID: 28778585
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
19. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
Kijima T; Yamamoto H; Saito K; Kusuhara S; Yoshida S; Yokoyama M; Matsuoka Y; Numao N; Sakai Y; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
Cancer Immunol Immunother; 2021 Mar; 70(3):657-665. PubMed ID: 32876736
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
